Cannabigerol modulates α2-adrenoceptor and 5-HT1A receptor-mediated electrophysiological effects on dorsal raphe nucleus and locus coeruleus neurons and anxiety behavior in rat

The pharmacological profile of cannabigerol (CBG), which acid form constitutes the main precursor of the most abundant cannabinoids, has been scarcely studied. It has been reported to target α2-adrenoceptor and 5-HT1A receptor. The locus coeruleus (LC) and the dorsal raphe nucleus (DRN) are the main serotonergic (5-HT) and noradrenergic (NA) areas in the rat brain, respectively. We aimed to study the effect of CBG on the firing rate of LC NA cells and DRN 5-HT cells and on α2-adrenergic and 5-HT1A autoreceptors by electrophysiological techniques in male Sprague-Dawley rat brain slices. The effect of CBG on the novelty-suppressed feeding test (NSFT) and the elevated plus maze test (EPMT) and the involvement of the 5-HT1A receptor was also studied. CBG (30 μM, 10 min) slightly changed the firing rate of NA cells but failed to alter the inhibitory effect of NA (1–100 µM). However, in the presence of CBG the inhibitory effect of the selective α2-adrenoceptor agonist UK14304 (10 nM) was decreased. Perfusion with CBG (30 μM, 10 min) did not change the firing rate of DRN 5-HT cells or the inhibitory effect of 5-HT (100 μM, 1 min) but it reduced the inhibitory effect of ipsapirone (100 nM). CBG failed to reverse ipsapirone-induced inhibition whereas perfusion with the 5-HT1A receptor antagonist WAY100635 (30 nM) completely restored the firing rate of DRN 5-HT cells. In the EPMT, CBG (10 mg/kg, i.p.) significantly increased the percentage of time the rats spent on the open arms and the number of head-dipping but it reduced the anxiety index. In the NSFT, CBG decreased the time latency to eat in the novel environment but it did not alter home-cage consumption. The effect of CBG on the reduction of latency to feed was prevented by pretreatment with WAY100635 (1 mg/kg, i.p.). In conclusion, CBG hinders the inhibitory effect produced by selective α2-adrenoceptor and 5-HT1A receptor agonists on the firing rate of NA-LC and 5-HT-DRN neurons by a yet unknown indirect mechanism in rat brain slices and produces anxiolytic-like effects through 5-HT1A receptor.

[1]  A. Pérez-Samartín,et al.  Functional characterization of cannabidiol effect on the serotonergic neurons of the dorsal raphe nucleus in rat brain slices , 2022, Frontiers in Pharmacology.

[2]  Wendong Huang,et al.  A narrative review of molecular mechanism and therapeutic effect of cannabidiol (CBD) , 2022, Basic & clinical pharmacology & toxicology.

[3]  H. Ishiguro,et al.  New Insights and Potential Therapeutic Targeting of CB2 Cannabinoid Receptors in CNS Disorders , 2022, International journal of molecular sciences.

[4]  C. Soriano-Mas,et al.  The Role of the Locus Coeruleus in Pain and Associated Stress-Related Disorders , 2021, Biological Psychiatry.

[5]  N. Assareh,et al.  The Cannabis Constituent Cannabigerol Does Not Disrupt Fear Memory Processes or Stress-Induced Anxiety in Mice. , 2021, Cannabis and Cannabinoid Research.

[6]  R. Freire,et al.  Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options , 2021, Focus.

[7]  M. Casarejos,et al.  Neuroprotection with the cannabigerol quinone derivative VCE-003.2 and its analogs CBGA-Q and CBGA-Q-Salt in Parkinson's disease using 6-hydroxydopamine-lesioned mice , 2020, Molecular and Cellular Neuroscience.

[8]  K. Vrana,et al.  The Pharmacological Case for Cannabigerol , 2020, The Journal of Pharmacology and Experimental Therapeutics.

[9]  C. Stevenson,et al.  In it together? The case for endocannabinoid–noradrenergic interactions in fear extinction , 2021, The European journal of neuroscience.

[10]  Z. Xi,et al.  Possible Receptor Mechanisms Underlying Cannabidiol Effects on Addictive-like Behaviors in Experimental Animals , 2020, International journal of molecular sciences.

[11]  R. Freire,et al.  Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options , 2020, Frontiers in Psychiatry.

[12]  R. Laprairie,et al.  In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa , 2020, Scientific Reports.

[13]  E. Mazzon,et al.  Molecular Targets of Cannabidiol in Experimental Models of Neurological Disease , 2020, Molecules.

[14]  M. Reyes-Parada,et al.  A Comparative In Vitro Study of the Neuroprotective Effect Induced by Cannabidiol, Cannabigerol, and Their Respective Acid Forms: Relevance of the 5-HT1A Receptors , 2020, Neurotoxicity research.

[15]  R. Arslan,et al.  The anxiolytic effect of perampanel and possible mechanisms mediating its anxiolytic effect in mice. , 2020, Life sciences.

[16]  D. Charney,et al.  The role of the locus coeruleus in the generation of pathological anxiety , 2020, Brain and neuroscience advances.

[17]  A. Cataldi,et al.  Neuroprotective and Neuromodulatory Effects Induced by Cannabidiol and Cannabigerol in Rat Hypo-E22 cells and Isolated Hypothalamus , 2020, Antioxidants.

[18]  P. Albert,et al.  The 5-HT1A receptor: Signaling to behavior. , 2019, Biochimie.

[19]  R. McLaughlin,et al.  Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain , 2018, Pain.

[20]  F. Guimarães,et al.  Antidepressant-like effect induced by Cannabidiol is dependent on brain serotonin levels , 2018, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[21]  R. Franco,et al.  Cannabigerol Action at Cannabinoid CB1 and CB2 Receptors and at CB1–CB2 Heteroreceptor Complexes , 2018, Front. Pharmacol..

[22]  J. Pineda,et al.  Regulation of noradrenergic and serotonergic systems by cannabinoids: relevance to cannabinoid‐induced effects , 2018, Life sciences.

[23]  J. Pineda,et al.  Characterization of functional μ opioid receptor turnover in rat locus coeruleus: an electrophysiological and immunocytochemical study , 2017, British journal of pharmacology.

[24]  Benjamin J. Whalley,et al.  Molecular Pharmacology of Phytocannabinoids. , 2017, Progress in the chemistry of organic natural products.

[25]  M. Morgan,et al.  Relative contribution of the dorsal raphe nucleus and ventrolateral periaqueductal gray to morphine antinociception and tolerance in the rat , 2016, The European journal of neuroscience.

[26]  Benjamin J. Whalley,et al.  Cannabigerol is a novel, well-tolerated appetite stimulant in pre-satiated rats , 2016, Psychopharmacology.

[27]  Jean-Claude Béïque,et al.  Target-specific modulation of the descending prefrontal cortex inputs to the dorsal raphe nucleus by cannabinoids , 2016, Proceedings of the National Academy of Sciences.

[28]  F. Guimarães,et al.  Antidepressant-like effect of cannabidiol injection into the ventral medial prefrontal cortex—Possible involvement of 5-HT1A and CB1 receptors , 2016, Behavioural Brain Research.

[29]  F. Pilar-Cuéllar,et al.  Cannabidiol induces rapid-acting antidepressant-like effects and enhances cortical 5-HT/glutamate neurotransmission: role of 5-HT1A receptors , 2016, Neuropharmacology.

[30]  C. P. Ford,et al.  Mechanisms of 5‐HT1A receptor‐mediated transmission in dorsal raphe serotonin neurons , 2016, The Journal of physiology.

[31]  F. Guimarães,et al.  Effects of intra-infralimbic prefrontal cortex injections of cannabidiol in the modulation of emotional behaviors in rats: Contribution of 5HT1A receptors and stressful experiences , 2015, Behavioural Brain Research.

[32]  M. Bellido,et al.  A Cannabigerol Derivative Suppresses Immune Responses and Protects Mice from Experimental Autoimmune Encephalomyelitis , 2014, PloS one.

[33]  M. Bellido,et al.  Neuroprotective Properties of Cannabigerol in Huntington’s Disease: Studies in R6/2 Mice and 3-Nitropropionate-lesioned Mice , 2014, Neurotherapeutics.

[34]  H. Cohen,et al.  Animal Models of Post‐Traumatic Stress Disorder , 2013, Current protocols in neuroscience.

[35]  K. Antoniou,et al.  The cannabinoid CB1 receptor biphasically modulates motor activity and regulates dopamine and glutamate release region dependently. , 2013, The international journal of neuropsychopharmacology.

[36]  C. Limebeer,et al.  Effect of chronic exposure to rimonabant and phytocannabinoids on anxiety-like behavior and saccharin palatability , 2013, Pharmacology Biochemistry and Behavior.

[37]  G. Gobbi,et al.  Effect of delta-9-tetrahydrocannabinol on behavioral despair and on pre- and postsynaptic serotonergic transmission , 2012, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[38]  Benjamin J. Whalley,et al.  Cannabinol and cannabidiol exert opposing effects on rat feeding patterns , 2012, Psychopharmacology.

[39]  P. Fletcher,et al.  Cannabidiol, a non‐psychotropic component of cannabis, attenuates vomiting and nausea‐like behaviour via indirect agonism of 5‐HT1A somatodendritic autoreceptors in the dorsal raphe nucleus , 2012, British journal of pharmacology.

[40]  L. Hunyady,et al.  Opposing local effects of endocannabinoids on the activity of noradrenergic neurons and release of noradrenaline: relevance for their role in depression and in the actions of CB1 receptor antagonists , 2012, Journal of Neural Transmission.

[41]  B. Platt,et al.  Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), Δ9-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive–compulsive behaviour , 2012, Psychopharmacology.

[42]  A. Dunn,et al.  Participation of brainstem monoaminergic nuclei in behavioral depression , 2011, Pharmacology Biochemistry and Behavior.

[43]  N. Coimbra,et al.  Paradoxical effect of noradrenaline-mediated neurotransmission in the antinociceptive phenomenon that accompanies tonic–clonic seizures: Role of locus coeruleus neurons and α2- and β-noradrenergic receptors , 2011, Epilepsy & Behavior.

[44]  J. Neumaier,et al.  Regulation of dorsal raphe nucleus function by serotonin autoreceptors: A behavioral perspective , 2011, Journal of Chemical Neuroanatomy.

[45]  J. Manzanares,et al.  Overexpression of CB2 cannabinoid receptors decreased vulnerability to anxiety and impaired anxiolytic action of alprazolam in mice , 2011, Journal of psychopharmacology.

[46]  C. Limebeer,et al.  Interaction between non-psychotropic cannabinoids in marihuana: effect of cannabigerol (CBG) on the anti-nausea or anti-emetic effects of cannabidiol (CBD) in rats and shrews , 2011, Psychopharmacology.

[47]  J. Monti The structure of the dorsal raphe nucleus and its relevance to the regulation of sleep and wakefulness. , 2010, Sleep medicine reviews.

[48]  Abigail M Polter,et al.  5-HT1A receptor-regulated signal transduction pathways in brain. , 2010, Cellular signalling.

[49]  Y. Kayama,et al.  Locus coeruleus neuronal activity during the sleep-waking cycle in mice , 2010, Neuroscience.

[50]  Benjamin J. Whalley,et al.  Cannabidiol Displays Antiepileptiform and Antiseizure Properties In Vitro and In Vivo , 2010, Journal of Pharmacology and Experimental Therapeutics.

[51]  R. Pertwee,et al.  Evidence that the plant cannabinoid cannabigerol is a highly potent α2‐adrenoceptor agonist and moderately potent 5HT1A receptor antagonist , 2010, British journal of pharmacology.

[52]  C. Biojone,et al.  Antidepressant‐like effects of cannabidiol in mice: possible involvement of 5‐HT1A receptors , 2010, British journal of pharmacology.

[53]  J. Pineda,et al.  Effect of the CB1 receptor antagonists rimonabant and AM251 on the firing rate of dorsal raphe nucleus neurons in rat brain slices , 2009, British journal of pharmacology.

[54]  F. Guimarães,et al.  5‐HT1A receptors are involved in the cannabidiol‐induced attenuation of behavioural and cardiovascular responses to acute restraint stress in rats , 2009, British journal of pharmacology.

[55]  J. Kelly,et al.  Comparison of the behavioural pharmacology of the Lister-Hooded with 2 commonly utilised albino rat strains , 2008, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[56]  Anantha Shekhar,et al.  Serotonergic Systems, Anxiety, and Affective Disorder , 2008, Annals of the New York Academy of Sciences.

[57]  Christoph Schmitz,et al.  The dorsal raphe nucleus—From silver stainings to a role in depression , 2007, Brain Research Reviews.

[58]  A. Walf,et al.  The use of the elevated plus maze as an assay of anxiety-related behavior in rodents , 2007, Nature Protocols.

[59]  Xiaohong Ma,et al.  Selective 5‐HT1B receptor inhibition of glutamatergic and GABAergic synaptic activity in the rat dorsal and median raphe , 2006, The European journal of neuroscience.

[60]  M. Pistis,et al.  Cannabinoids modulate spontaneous neuronal activity and evoked inhibition of locus coeruleus noradrenergic neurons , 2006, The European journal of neuroscience.

[61]  T. Cassano,et al.  Correction for Gobbi et al., Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[62]  J. Pineda,et al.  α2-Adrenoceptor involvement in the in vitro inhibitory effect of citalopram on a subpopulation of rat locus coeruleus neurons , 2005 .

[63]  J. Pineda,et al.  Cannabinoids enhance N-methyl-d-aspartate-induced excitation of locus coeruleus neurons by CB1 receptors in rat brain slices , 2004, Neuroscience Letters.

[64]  J. Kew,et al.  GABAergic modulation of 5-HT7 receptor-mediated effects on 5-HT efflux in the guinea-pig dorsal raphe nucleus , 2004, Neuropharmacology.

[65]  J. Bockaert,et al.  Differential coupling of 5-HT1A receptors occupied by 5-HT or 8-OH-DPAT to adenylyl cyclase , 1992, Naunyn-Schmiedeberg's Archives of Pharmacology.

[66]  P. L. Broadhurst,et al.  Hyponeophagia and arousal in rats: Effects of diazepam, 5-methoxy-N,N-dimethyltryptamine, d-amphetamine and food deprivation , 2004, Psychopharmacology.

[67]  T. Kirkham,et al.  Observational analysis of feeding induced by Δ9-THC and anandamide , 2002, Physiology & Behavior.

[68]  P. Celada,et al.  The role of 5‐HT1B receptors in the regulation of serotonin cell firing and release in the rat brain , 2001, Journal of neurochemistry.

[69]  J. Williams,et al.  Regulation of central synaptic transmission by 5-HT(1B) auto- and heteroreceptors. , 2000, Molecular pharmacology.

[70]  Jonathan D. Cohen,et al.  Role of locus coeruleus in attention and behavioral flexibility , 1999, Biological Psychiatry.

[71]  L. Lanfumey,et al.  Antagonist properties of (−)‐pindolol and WAY 100635 at somatodendritic and postsynaptic 5‐HT1A receptors in the rat brain , 1998, British journal of pharmacology.

[72]  G. Perrault,et al.  Risk Assessment Behaviour: Evaluation of Utility in the Study of 5-HT-Related Drugs in the Rat Elevated Plus-Maze Test , 1997, Pharmacology Biochemistry and Behavior.

[73]  K. Starke,et al.  Subtype determination of soma-dendritic α2-autoreceptors in slices of rat locus coeruleus , 1997, Naunyn-Schmiedeberg's Archives of Pharmacology.

[74]  Trevor Sharp,et al.  Intracellular recordings from burst-firing presumed serotonergic neurones in the rat dorsal raphe nucleus in vivo , 1996, Brain Research.

[75]  T. Chiu,et al.  Action of dexmedetomidine on rat locus coeruleus neurones: intracellular recording in vitro. , 1995, European journal of pharmacology.

[76]  F. Graeff,et al.  Ethopharmacological analysis of rat behavior on the elevated plus-maze , 1994, Pharmacology Biochemistry and Behavior.

[77]  S. Haj-Dahmane,et al.  K+ channel and 5-hydroxytryptamine1A autoreceptor interactions in the rat dorsal raphe nucleus: Anin vitro electrophysiological study , 1991, Neuroscience.

[78]  G. Aghajanian,et al.  Common α2- and opiate effector mechanisms in the locus coeruleus: intracellular studies in brain slices , 1987, Neuropharmacology.

[79]  G. Aghajanian,et al.  Hyperpolarization of serotonergic neurons by serotonin and LSD: Studies in brain slices showing increased K+ conductance , 1984, Brain Research.

[80]  G. Aghajanian,et al.  Locus coeruleus activity in vitro: intrinsic regulation by a calcium- dependent potassium conductance but not alpha 2-adrenoceptors , 1984, The Journal of neuroscience : the official journal of the Society for Neuroscience.